Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals

World J Gastroenterol. 2019 Mar 21;25(11):1327-1340. doi: 10.3748/wjg.v25.i11.1327.

Abstract

Background: Hepatitis C virus (HCV) is a leading cause of worldwide liver-related morbidity and mortality. The World Health Organization released an integrated strategy targeting HCV-elimination by 2030. This study aims to estimate the required interventions to achieve elimination using updated information for direct-acting antiviral (DAA) treatment coverage, to compute the total costs (including indirect/societal costs) of the strategy and to identify whether the elimination strategy is cost-effective/cost-saving in Greece.

Aim: To estimate the required interventions and subsequent costs to achieve HCV elimination in Greece.

Methods: A previously validated mathematical model was adapted to the Greek HCV-infected population to compare the outcomes of DAA treatment without the additional implementation of awareness or screening campaigns versus an HCV elimination strategy, which includes a sufficient number of treated patients. We estimated the total costs (direct and indirect costs), the disability-adjusted life years and the incremental cost-effectiveness ratio using two different price scenarios.

Results: Without the implementation of awareness or screening campaigns, approximately 20000 patients would be diagnosed and treated with DAAs by 2030. This strategy would result in a 19.6% increase in HCV-related mortality in 2030 compared to 2015. To achieve the elimination goal, 90000 patients need to be treated by 2030. Under the elimination scenario, viremic cases would decrease by 78.8% in 2030 compared to 2015. The cumulative direct costs to eliminate the disease would range from 2.1-2.3 billion euros (€) by 2030, while the indirect costs would be €1.1 billion. The total elimination cost in Greece would range from €3.2-3.4 billion by 2030. The cost per averted disability-adjusted life year is estimated between €10100 and €13380, indicating that the elimination strategy is very cost-effective. Furthermore, HCV elimination strategy would save €560-895 million by 2035.

Conclusion: Without large screening programs, elimination of HCV cannot be achieved. The HCV elimination strategy is feasible and cost-saving despite the uncertainty of the future cost of DAAs in Greece.

Keywords: Awareness and screening programs; Cost effectiveness; Cost of elimination; Hepatitis C elimination; Indirect costs; Mathematical modelling; Projections; World Health Organization targets.

MeSH terms

  • Antiviral Agents / economics
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Cost Savings
  • Cost of Illness
  • Cost-Benefit Analysis*
  • Disease Eradication / economics*
  • Disease Eradication / methods
  • Disease Eradication / organization & administration
  • Feasibility Studies
  • Greece
  • Health Care Costs*
  • Health Knowledge, Attitudes, Practice
  • Health Plan Implementation / economics
  • Health Plan Implementation / organization & administration
  • Health Services Needs and Demand / economics
  • Hepacivirus / drug effects
  • Hepacivirus / isolation & purification
  • Hepatitis C / economics
  • Hepatitis C / prevention & control*
  • Hepatitis C / virology
  • Humans
  • Insurance Coverage / economics
  • Insurance, Health / economics
  • Mass Screening / economics
  • Mass Screening / organization & administration
  • Patient Education as Topic / economics
  • Quality-Adjusted Life Years

Substances

  • Antiviral Agents